Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
Introduction. A number of drugs, which improve overall survival and quality of patients' life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatme...
में बचाया:
| मुख्य लेखकों: | , , |
|---|---|
| स्वरूप: | पुस्तक |
| प्रकाशित: |
IRBIS LLC,
2019-01-01T00:00:00Z.
|
| विषय: | |
| ऑनलाइन पहुंच: | Connect to this object online. |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
टिप्पणी देने वाले पहले व्यक्ति बनें!